MMIT (Managed Markets Insight & Technology)’s Post

The oncology space is no longer subject to minimal payer management. MMIT’s Jory Fleischauer discusses utilization management and the likely rise in competitive contracting coming to this therapeutic area. Read now: https://ow.ly/7X9S50Rlykx #OncologyTherapies #CancerCare #PayerManagement #Oncology

Florida Cancer Specialists & Research Institute (FCS) is set to enhance its distributor partnerships, reinforcing scalability through their management services organization (MSO). The strategic move aligns with the increasing demand for value-based care in the evolving oncology market. #Pharmaceuticals #Oncology #HealthcareRevolution

The FDA’s Oncology Center of Excellence has launched a crowdsourcing initiative to identify five clinically relevant questions regarding FDA-approved #oncology therapies to be addressed through #pragmaticclinicaltrials over the next five years. Read at The Evidence Base® #outcomesresearch #rwe #rwd #realworldevidence #realworlddata #regulation #regulatoryaffairs #healthdata #clinicaltrial #randomzedcontrolledtrial

How oncology studies can streamline trial operations The upcoming CTO East Coast 2024 will focus on solutions that address the challenges and innovations faced by oncology programs. - https://lnkd.in/dUtVYCKZ #clinicaltrials #oncology #clinicaloperations

🌐 ASCO 2024: ONCOassist®Garners Global Support A recent article published in the Journal of Clinical Oncology shows positive feedback on the use of NCCN templates by global oncologists. 🤔 Impact on Pharma Media: How can other Oncology focused apps learn from this, harness this feedback and engage more effectively with global oncologists? #solli #solliglobal #globalpharmmedia #asco24 #asco #nccn

Simplify your oncology trials and plan ahead with YPrime's latest oncology infographic here:

Our goal at Zelta is to simplify the complex world of oncology trials. Here is good information about the trends in oncology trials starting in 2024. Thanks Walker Bradham for all that you and the development team do to support our clients to be more efficient and reduce their burden of managing clinical trials. #clinicaldatamanagement #clinicaltrials #zelta #merative

Great conversation with Jennifer Nelson @MDedge! Although there are countless additional metrics, here are 7 basic KPIs oncology practices should be tracking.

🛑 IK-930 Clinical Trial Discontinued Many of you have heard the disappointing news that Ikena Oncology has announced they are discontinuing the development of IK-930. We share your frustration and disappointment, understand the devastating impact felt by patients, and are working hard to advocate for patients. We urge you to read our statement in our latest blog post: https://lnkd.in/eyy6an88

Unlocking the full picture in cancer treatment goes beyond survival – it's about enhancing Quality of Life (QoL). Read Kelly Dumais's article on how prioritizing patient-reported outcomes (PROs) can enhance study designs and elevate your drug's market position: • PROs in study design: Uncover how patient insights enhance oncology trials. • Therapy differentiation: Learn the role of PROs in setting your product apart. • ePRO advantages: Streamline trials with effective electronic data collection. • Regulatory compliance: Align your trials with FDA and EMA expectations through patient-centric strategies. Gain valuable insights on integrating PROs effectively: https://hubs.li/Q02clxsG0